# R-GemOx

Type: Product

Source: GetYourBrief — https://getyourbrief.com/entity/r-gemox
Canonical HTML page: https://getyourbrief.com/entity/r-gemox

## Recent coverage (2 stories, network-wide)

### Phase 3: Epcoritamab Combo Cuts DLBCL Progression Risk by 60%
2026-07-11 23:08:35 · Sector: health · Sentiment: Strongly positive · Impact: 8/10 · Sources: 3

A fixed-duration bispecific antibody plus lenalidomide dramatically improved progression-free survival over standard salvage chemoimmunotherapy in relapsed/refractory DLBCL, potentially offering healthcare systems a more effective and less toxic outpatient option while reshaping treatment guidelines and resource utilization.
Full story: https://gethealthbrief.com/story/epcoritamab-lenalidomide-phase3-dlbcl-60-percent-risk-reduction-health

### Epcoritamab-Lenalidomide Hits Phase 3 PFS Goals: 60% Risk Reduction
2026-07-11 23:08:27 · Sector: bio · Sentiment: Strongly positive · Impact: 8/10 · Sources: 3

AbbVie and Genmab's bispecific antibody epcoritamab combined with lenalidomide delivered a hazard ratio of 0.40 in a pivotal DLBCL trial, setting the stage for regulatory filings and a potential second-line market expansion that could challenge CAR-T dominance and redefine the bispecific landscape.
Full story: https://getbiobrief.com/story/epcoritamab-lenalidomide-phase3-dlbcl-biotech-abbv-gmab

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.